- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01490879
A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE) (DUNE)
A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon® in the Treatment of Subjects With a Diabetic Foot Ulcer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kemerovo, Russian Federation, 650066
- Kemerovo Regional Clinical Hospital
-
Moscow, Russian Federation, 1154280
- City Clinical Hospital #13
-
Moscow, Russian Federation, 117036
- Endocrinology Science Center
-
Moscow, Russian Federation, 119034
- Endocrinology Clinic of Moscow, Department of Healthcare
-
Moscow, Russian Federation, 119435
- Moscow Medical University n.a.
-
Moscow, Russian Federation, 127486
- Federal bureau of medical and social expertise, Moscow
-
St Petersburg, Russian Federation, 198099
- St Petersburg City Hospital of St Elizabeth
-
St Petersburg, Russian Federation, 198255
- St Petersburg Diagnostic Center
-
Voronezh, Russian Federation
- Voronezh Regional Clinical Consultative Diagnostic Center
-
-
-
-
-
Cherkasy, Ukraine, 18009
- Cherkasy Regional Clinical Hospital, Endocrinology Department
-
Dnipropetrovsk, Ukraine, 49005
- Dnipropetrovsk Regional Clinical Hospitaln. a. I.I. Mechnikov
-
Ivano-Frankivsk, Ukraine, 76025
- Ivano-Frankivsk Central City Clinical Hospital
-
Kharkiv, Ukraine, 61022
- Regional Clinical Hospital, Cardiovascular Surgery Department
-
Kyiv, Ukraine, 02091
- Kyiv City Clinical Hospital #1
-
Kyiv, Ukraine, 04114
- Institute of Endocrinology and Methabolism n.a. V.P. Komisarenko, Clinical Diabetology Department
-
Zaporizhzhya, Ukraine, 69096
- Zaporizhzhya City Clinical Hospital #9
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
- Associated Foot and Ankle Specialists, LLC
-
Tucson, Arizona, United States, 85724
- University of Arizona Medical Center
-
-
California
-
Castro Valley, California, United States, 94546
- Center for Clinical Research Inc.
-
Fresno, California, United States, 93722
- Advanced Foot Care And Clinical Research Center
-
-
Florida
-
Hialeah, Florida, United States, 33013
- Barry University Clinical Research
-
Miami, Florida, United States, 33136
- Univeristy of Miami, Miller School of Medicine, Dermatology Research
-
South Miami, Florida, United States, 33143
- Doctors Research Network
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- Advanced Foot and Ankle Center
-
-
Texas
-
Houston, Texas, United States, 77074
- Houston Foot and Ankle Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of diabetes mellitus (Type I or II)
- HbA1c of less than or equal to 12.0%
- Diagnosis of neuropathic foot ulcer with partial or complete neuropathy
- Cutaneous ulcer on the plantar or dorsal aspect of the foot or toe that is greater or equal to 1.0cm2 and less than or equal to 8.0 cm2 in area at the end of the screening period and is full thickness with no exposed ligament, tendon, joint capsule or bone. Surface area will be measured by digital planimetry.
- The Medical Monitor(or delegate)must confirm that the reference diabetic foot ulcer (RDFU)is suitable for inclusion after reviewing digital photographs
- Wound bed consisting of completely viable tissue or one where completely viable tissue will be achieved by the end of the screening period.
- An Ankle Branchial Index (ABI) of greater or equal to 0.80 in concert with a bi- or tri-phasic Doppler flow pattern; or adequate circulation as demonstrated by any of the following methods: peri-wound transcutaneous partial pressure oxygen (TcpO2)greater or equal to 40 mmHg; or a toe pressure of greater or equal to 40 mmHg; or skin perfusion pressure of greater or equal to 40 mmHg.
- Ulcer present for 4 weeks or more or less than or equal to 12 months.
- Willing to wear a Removable Cast Walker (RCW) between study visits for the duration of the study.
- Signed informed consent form.
Exclusion Criteria:
- Any unstable medical condition that would cause the study to be detrimental to the subject.
- Decrease in RDFU size by more than 40% or increase in the ulcer size by more than 40% during the 14-day screening period as measured by digital planimetry.
- Ulcers caused primarily by untreated vascular insufficiency or ulcers with an etiology not related to diabetes.4. Ulcers above the ankle.
5. Ulcers that cannot be effectively off-loaded using the cast walker and sole insert provided in this study (ulcers not located on the weight bearing surface of the foot do not require off-loading).
6. Ulcers on the toes not accessible for photography (e.g. in the web space). 7. Presence of other ulcers within 2cm of the perimeter of the RDFU. 8. BMI > 45 9. Cannot tolerate or will not comply with the off-loading method, or non-compliance with standard or care.
10.The RDFU is infected (clinical assessment of infection)and/or biopsy proof of greater than 100,000 organisms per gram of tissue during the screening period.
11. Subjects presenting with the clinical characteristics of cellulitis at the ulcer site. 12. Necrosis, purulence, or sinus tracts that cannot be removed by debridement.13. Definite or suspected osteomyelitis within any wound located anywhere on the subjects body.14. Acute Charcot's neuroarthropathy as determined by clinical and/or previous radiographic examination.
15. Severe Charcot deformity or rocker bottom foot with an associated plantar mid-foot or heel ulcer.
16. Revascularization surgery on the leg with the wound to be treated less than or equal to 4 weeks prior to the start of the screening period.
17. Requirement for concurrent topical antimicrobials to treat the RDFU after the end of the screening period.
18. Received dermal substitute or living skin equivalent (e.g. Dermagraft® or Apligraf®) within 14 days prior of the start of the screening period.
19. Severe complications of diabetes that in the opinion of the Investigator could interfere with wound healing or impede the subject's participation.
20. Subjects on concurrent immunosuppressive therapy to include oral corticosteroid therapy equivalent to greater than 5 mg/day of prednisone.
21. Any history of radiation therapy to the foot. 22. Female subjects who are pregnant or lactating. 23. Pre-menopausal women not using effective birth control methods as determined by the Investigator. 24. Life expectancy of < 12 months. 25. Subjects on renal replacement therapy. 26. Cancer within the last 3 years except basal and squamous cell carcinoma. 27. Cancer within the RDFU
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nexagon® Low Dose
Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
|
Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
|
Experimental: Nexagon® Medium Dose
Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
|
Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
|
Experimental: Nexagon® High Dose
Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
|
Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
|
Placebo Comparator: Nexagon® vehicle
Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
|
Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment
Time Frame: Within 12 weeks
|
Within 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events
Time Frame: 12 weeks
|
12 weeks
|
Percentage change in RDFU surface area
Time Frame: Within 12 weeks
|
Within 12 weeks
|
Time to RDFU complete closure
Time Frame: Within 12 weeks
|
Within 12 weeks
|
Percentage of granulation tissue in RDFU
Time Frame: 12 weeks
|
12 weeks
|
Incidence of ulcer recurrence
Time Frame: 12 weeks post-closure
|
12 weeks post-closure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David G Armstrong, DPM MD PhD, S.A.L.S.A. , University of Arizona, Tucson, AZ
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEX-ULC-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
Oneness Biotech Co., Ltd.Completed
-
Hadassah Medical OrganizationUnknown
-
Systagenix Wound ManagementUnknownDiabetic Foot UlcersItaly, United States, United Kingdom, Germany, Spain
-
Southern California Institute for Research and...Heritage Medical Research InstituteUnknownDiabetic Foot UlcersUnited States
Clinical Trials on Nexagon® Low Dose
-
OcuNexus Therapeutics, Inc.CompletedVenous Leg UlcersUnited States, New Zealand, South Africa, Australia
-
Amber Ophthalmics, Inc.RecruitingCorneal Persistent Epithelial DefectUnited States
-
OcuNexus Therapeutics, Inc.CompletedVenous UlcerNew Zealand, United States
-
OcuNexus Therapeutics, Inc.TerminatedDiabetic Foot UlcerNew Zealand
-
OcuNexus Therapeutics, Inc.WithdrawnPersistent Epithelial Defect
-
Amber Ophthalmics, Inc.RecruitingPersistent Corneal Epithelial DefectUnited States
-
GeneScience Pharmaceuticals Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaboratorsUnknown
-
Boehringer IngelheimCompleted
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Hypersensitivity, Immediate | Peanut HypersensitivityUnited States
-
Affiris AGMedical University Innsbruck; Forschungszentrum Juelich; PROSENEX AmbulatoriumbetriebsGMBHCompletedParkinson Disease | Neurodegenerative DiseasesAustria